“We hope to give clinicians a comprehensive, comparative view of which drugs do what and in which people,” said GRADE Principal Investigator David Nathan, MD. “It’s about time that we started to find out how these different drugs act in different populations.” GRADE results will be presented at 4:30 p.m. ET.
Monday afternoon at the Scientific Sessions: Results from head-to-head trial of four type 2 diabetes agents to be presented
